

Title: Protocol guidance for high risk trials and CTIMPs

Effective Date: 5-11-18

Review Date: 5-11-21

Author: Clinical Research Operational Group

QA Approval: Richard Cowie, QA Manager

Approver: Prof Maggie Cruickshank, R&D Director


Approver: Prof Steve Heys, Head of School

Document History

Version	Description of update	Date Effective
1	Change of number for Q-Pulse and correction of associated documents	2-10-15
2	Reformatted Clarification of version numbering at 3.2 Inclusion of laboratory if laboratory analysis is included in protocol 3.4	1-4-17
3	Clarification of version date at 3.3	26-1-18
4	Change of author Clarification of signatures required in protocol at 3.4 Reference to protocol being publically available at 3.9	5-11-18

1. Scope

1.1 This SOP applies to all research and Sponsor staff participating in, or supporting high risk trials, Clinical Trials of Investigational Medicinal Product (CTIMPs) and Medical Device Clinical Investigations sponsored or co-sponsored by University of Aberdeen (UoA) and/or NHS Grampian (NHSG).

1.2  Interventional and non-interventional research projects must have a protocol prepared which is compliant with the principles of Good Clinical Practice (GCP).


1.3 This SOP may also be used by staff from other NHS areas, or organisations, with prior agreement.


2. Responsibilities

Chief Investigator (CI)	Designing and writing the protocol compliant with the principles of GCP and relevant regulations, appropriate to the research.
Sponsor	Ensure any amendments to the protocol are managed correctly.
Research Monitors	Monitoring researchers against the current protocol.



3. Procedure


CTIMPs, Medical Device Clinical Investigations and high risk research protocols


3.1  The CI, or delegate, must use the Health Research Authority (HRA) Protocol Template, available from the HRA website, unless previously discussed and agreed with the Sponsor.


3.2  All protocols shall be version controlled; 'Draft 1', 'Draft 2' 'Draft 3' etc before being finalised, and then 'V1', 'V2', 'V3' etc. Versions shall never be 0.1, 1.1, 1.2, 1.3 etc.

Uncontrolled when printed. Please ensure that you are working on the most up to date version of this SOP.

Key to symbols  = Important point to note  = Warning


3.3  All pages shall be numbered and include the EudraCT number, version number, version date and the study title (or acronym).

3.4  The Approval Page shall be signed and dated by the Sponsor representative, CI, the individual responsible for statistical review and any other appropriate trial staff **prior** to distribution. If a trial involves a medicinal product, the Clinical Trial Pharmacist must also sign the protocol (please note that the HRA template does not include the Clinical trial Pharmacist and this should be added when required). If laboratory analysis is included in the protocol, the CI must ensure the appropriate laboratory representative (eg Laboratory Manager) has been involved prior to finalising the protocol.


 By signing the protocol the individuals concerned are making a formal agreement to adhere to it at all times.

3.5 Where appropriate, the protocol may refer to information listed in other documents eg the Summary of Product Characteristics (SPC), Investigator Brochure (IB), Trial Steering Committee (TSC) or Data Monitoring Committee (DMC) remit and membership.

3.6 If separate site specific information relating to the protocol is required (eg local handling procedures, storage etc) this shall be provided as an appendix to the protocol.

3.7  All planned amendments to the protocol must be submitted in the first instance to the Research Governance Team.

3.8 All fully approved amended protocols are subject to the same processes listed above.

3.9  In the interests of transparency, University of Aberdeen and NHS-Grampian require that protocols are made publically available. This shall create an early scientific record of methodology, help with the review and publication and potentially reduce duplication of some research effort.

4. Abbreviations and definitions

CI	Chief Investigator
CTIMP	Clinical Trial of Investigational Medicinal Product
DMC	Data Monitoring Committee
EudraCT	European Union Drug Regulating Authorities Clinical Trials
GCP	Good Clinical Practice
HRA	Health Research Authority
IB	Investigator Brochure
SPC (or SmPC)	Summary of Product Characteristics
TSC	Trial Steering Committee

5. Related documentation and references

National Research Ethics Service/Health Research Authority website.

Uncontrolled when printed. Please ensure that you are working on the most up to date version of this SOP.

Key to symbols  = Important point to note  = Warning